1.https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00270-5/abstract 2.https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tepotinib-metastatic-non-small-cell-lung-cancer 3.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240398/ 4.https://www.nejm...
3.https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lazertinib-amivantamab-vmjw-non-small-lung-cancer 4.https://www.nejm.org/doi/full/10.1056/NEJMoa2403614 5.https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.8508 6.https://www.smmttx.com/wp-content/uploads...
https://www.cancer.org/cancer/lung-cancer/treating-non-small-cell/targeted-therapies.html#drugsthattargetcellswithegfrgenechanges [3] Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in ...
EGFR（Epidermal Growth Factor Receptor，表皮生长因子受体）基因突变是非小细胞肺癌（non-small-cell lung cancer, NSCLC）中最常见的激活突变。一代EGFR靶向药物吉非替尼治疗后的耐药机制中，最常见的是获得性的EGFR T790M，这部分患者可以接着使用第三代靶向药物奥希替尼继续治疗；其次是MET扩增（c-Mesenchymal-epit...
2021年,Lung Cancer 公布了III期ARCHER 1050研究的更新结果[3]:在中国人群中,达可替尼相对于吉非替尼,两组ORR分别为77.1% vs. 72.7%,PFS分别为16个月 vs. 9.2个月,OS分别为32.5个月和24.9个月,与研究总体人群、亚洲人群有一致的OS获益。 IRC评...
The activation of EGFR promotes the proliferation, invasion and metastasis of cancer cells, then EGFR inhibitors may be important new drugs for treatment of human cancer, and EGFR is the molecular targets. EGFR inhibitors include small molecular compounds and monoclonal antibody. The results of a ...
驱动基因。简单来说，人体内有一些基因一旦被激活，就会持续诱导肺泡上皮的无序增生行为，久而久之，就...
关键词 伏美替尼;表皮生长因子受体;酪氨酸激酶抑制剂;非小细胞肺癌;突变;有效性;安全性 Research progress of furmonertinib for EGFR-mutated non-small cell lung cancer GU Hangye,LYU Qing,CHEN Yong(Key Specialty of Clinical Pharmacy,the First Affiliated Hospital of Guangdong Pharmaceutical University,...
Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung Cancer Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer . J. Biomed. Biotechnol. 2011 , ... T Kosaka,E Yamaki,A Mogi...
[3]https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-amivantamab-vmjw-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer-indications [4]European Commission approves RYBREVANT®▼ (amivantamab...